Epistasis in sporadic Alzheimer's disease
暂无分享,去创建一个
Mario Cortina-Borja | Onofre Combarros | A. Smith | O. Combarros | D. Lehmann | M. Cortina-Borja | A. David Smith | Donald J. Lehmann
[1] V. Haroutunian,et al. Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population , 1999, Annals of neurology.
[2] M. Ilyas Kamboh,et al. A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism , 1995, Nature Genetics.
[3] M. Mattson. Pathways towards and away from Alzheimer's disease , 2004, Nature.
[4] Bruno Derudas,et al. Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.
[5] Takashi Asada,et al. Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease. , 2006, Human molecular genetics.
[6] C. Mariani,et al. Interaction between the APOE ɛ4 allele and the APH-1b c+651T>G SNP in Alzheimer's disease , 2008, Neurobiology of Aging.
[7] E. Tolosa,et al. α-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population , 1998, Neuroscience Letters.
[8] R. Perry,et al. Association studies of transforming growth factor‐β1 and Alzheimer's disease , 2005 .
[9] F. Panza,et al. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe , 2004, Experimental Gerontology.
[10] A. Pfeffer,et al. CYP46: A risk factor for Alzheimer's disease or a coincidence? , 2005, Neuroscience Letters.
[11] Gérard Siest,et al. Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study , 2003, Neuroscience Letters.
[12] M. Owen,et al. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease , 2001, Human Genetics.
[13] Barbara Borroni,et al. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. , 2006, Rejuvenation research.
[14] V. Moskvina,et al. Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late‐onset Alzheimer's disease , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[15] S. Duan,et al. Insulin-degrading enzyme and Alzheimer disease , 2004, Neurology.
[16] B. Strooper,et al. Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex , 2003, Neuron.
[17] M. Laakso,et al. INTERLEUKIN-6 PROMOTER POLYMORPHISM AND LATE-ONSET ALZHEIMER's DISEASE IN THE FINNISH POPULATION , 2005, Journal of neurogenetics.
[18] G. Perry,et al. Book Review: Is Alzheimer’s Disease a Mitochondrial Disorder? , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[19] H Jick,et al. Statins and the risk of dementia , 2000, The Lancet.
[20] L. Feuk,et al. Variants of CYP46A1 may interact with age and APOE to influence CSF Aβ42 levels in Alzheimer’s disease , 2004, Human Genetics.
[21] S. Sorbi,et al. Absence of association between Alzheimer disease and the regulatory region polymorphism of the PS2 gene in an Italian population , 2003, Neuroscience Letters.
[22] J. Nakura,et al. The 4,752 C/T polymorphism in the presenilin 1 gene increases the risk of Alzheimer's disease in apolipoprotein E4 carriers. , 2002, Internal medicine.
[23] J. Gilbert,et al. Interaction between the α-T catenin gene (VR22) and APOE in Alzheimer’s disease , 2005, Journal of Medical Genetics.
[24] S. McIlroy,et al. Association of serum AACT levels and AACT signal polymorphism with late‐onset Alzheimer's disease in Northern Ireland , 2000, International journal of geriatric psychiatry.
[25] Polymorphisms in cytoplasmic serine hydroxymethyltransferase and methylenetetrahydrofolate reductase affect the risk of cardiovascular disease in men. , 2005, The Journal of nutrition.
[26] M. Xiong,et al. A systems biology approach to genetic studies of complex diseases , 2005, FEBS letters.
[27] W. Markesbery,et al. Oxidized Low‐Density Lipoprotein Induces Neuronal Death , 1999, Journal of neurochemistry.
[28] O. Combarros,et al. Interaction between estrogen receptor-α and butyrylcholinesterase genes modulates Alzheimer’s disease risk , 2007, Journal of Neurology.
[29] Rena Li,et al. Microglia and inflammatory mechanisms in the clearance of amyloid β peptide , 2002 .
[30] P. Mecocci,et al. Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease , 2006, Journal of the Neurological Sciences.
[31] Zhenxin Zhang,et al. Association between Cathepsin D Polymorphism and Alzheimer’s Disease in a Chinese Han Population , 2004, Dementia and Geriatric Cognitive Disorders.
[32] M. Imagawa,et al. Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. , 2000, Biochemical and biophysical research communications.
[33] J. Lambert,et al. Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease , 2006, Neurobiology of Aging.
[34] D. Comas,et al. Association study between Alzheimer’s disease and genes involved in Aβ biosynthesis, aggregation and degradation: suggestive results with BACE1 , 2003, Journal of Neurology.
[35] E. Tangalos,et al. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE) , 2003, Neuroscience Letters.
[36] O. Combarros,et al. Interaction between interleukin–6 and intercellular adhesion molecule–1 genes and Alzheimer’s disease risk , 2005, Journal of Neurology.
[37] G. Forloni,et al. Tumor necrosis factor α polymorphism C-850T is not associated with Alzheimer's disease and vascular dementia in an Italian population , 2003, Neuroscience Letters.
[38] A. Hofman,et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.
[39] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[40] P. Passmore,et al. Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer disease in Northern Ireland. , 2001, American journal of medical genetics.
[41] Ze Yang,et al. Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese , 2004, Neuroscience Letters.
[42] B. Hernández-Charro,et al. El polimorfismo ACT/AA podría duplicar el riesgo de enfermedad de Alzheimer asociado al alelo APOE*ε4 , 2004 .
[43] C. Carter,et al. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis , 2007, Neurochemistry International.
[44] M. Esiri,et al. Accuracy of Clinical Operational Diagnostic Criteria for Alzheimer’s Disease in Relation to Different Pathological Diagnostic Protocols , 1998, Dementia and Geriatric Cognitive Disorders.
[45] J. Haines,et al. No Genetic Effect of α1-Antichymotrypsin in Alzheimer Disease , 1996 .
[46] S. Humphries,et al. The molecular genetics of cardiovascular disease: clinical implications , 2003, Journal of internal medicine.
[47] P. Bosco,et al. The CDC2 I-G-T haplotype associated with the APOE ɛ4 allele increases the risk of sporadic Alzheimer's disease in Sicily , 2007, Neuroscience Letters.
[48] Longfei Jia,et al. Genetic association between polymorphisms of Pen2 gene and late onset Alzheimer's disease in the North Chinese population , 2007, Brain Research.
[49] A. Singleton,et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. , 1998, Human molecular genetics.
[50] A. Smith,et al. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer’s disease and to identify high-risk subgroups , 2001, Neuroscience.
[51] J. Haines,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.
[52] A. Smith,et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease , 2004, Journal of Medical Genetics.
[53] Lin He,et al. An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray , 2005, European Journal of Human Genetics.
[54] O. Combarros,et al. Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.
[55] S. DeKosky,et al. Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease , 2000, Neuroscience Letters.
[56] Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.
[57] A. Smith,et al. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. , 1997, Human molecular genetics.
[58] T. Ogihara,et al. Low density lipoprotein receptor‐related protein gene polymorphisms and risk for late‐onset Alzheimer's disease in a Japanese population , 2000, Clinical genetics.
[59] Xiongwei Zhu,et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? , 2002, Free radical biology & medicine.
[60] Y. Christen,et al. Oxidative stress and Alzheimer disease. , 2000, The American journal of clinical nutrition.
[61] D. Sparks,et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. , 2005, Archives of general psychiatry.
[62] W. Maier,et al. SREBP-1a Polymorphism Influences the Risk of Alzheimer’s Disease in Carriers of the ApoE4 Allele , 2004, Dementia and Geriatric Cognitive Disorders.
[63] L. Lannfelt,et al. A DLST genotype associated with reduced risk for Alzheimer’s disease , 1999, Neurology.
[64] F. Rodríguez‐Artalejo,et al. Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender , 2000, Neuroscience Letters.
[65] J. Poirier. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. , 2003, Trends in molecular medicine.
[66] O. Combarros,et al. Interaction between dopamine β-hydroxylase and interleukin genes increases Alzheimer’s disease risk , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[67] Keith Hoots,et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS , 2002, Nature Genetics.
[68] O. Combarros,et al. Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer’s disease risk , 2007, Journal of Neurology.
[69] E. Corder,et al. Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer’s disease , 2005, Journal of Medical Genetics.
[70] O. Combarros,et al. Interaction between CYP19 Aromatase and Butyrylcholinesterase Genes Increases Alzheimer’s Disease Risk , 2005, Dementia and Geriatric Cognitive Disorders.
[71] M. Wade. Epistasis, complex traits, and mapping genes. , 2001 .
[72] J. Morris,et al. Association studies using novel polymorphisms in BACE1 and BACE2 , 2001, Neuroreport.
[73] R. Felder,et al. Combinations of variations in multiple genes are associated with hypertension. , 2000, Hypertension.
[74] Scott M. Williams,et al. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.
[75] F. Dudbridge,et al. Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes , 2004, Genes and Immunity.
[76] E. Sinforiani,et al. Estrogen receptor α and APOEɛ4 polymorphisms interact to increase risk for sporadic AD in Italian females , 2006 .
[77] A. Hofman,et al. The α2-macroglobulin gene in AD , 2000, Neurology.
[78] E. Gaetani,et al. Proinflammatory Genetic Profiles in Subjects With History of Ischemic Stroke , 2004, Stroke.
[79] J. Herz. The LDL Receptor Gene Family (Un)Expected Signal Transducers in the Brain , 2001, Neuron.
[80] F. Jessen,et al. Gene‐gene interaction between interleukin‐6 and α2‐macroglobulin influences the risk for Alzheimer's disease , 2000 .
[81] K. Morgan,et al. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease , 1999, European Journal of Human Genetics.
[82] P. Deyn,et al. Association study of cholesterol-related genes in Alzheimer’s disease , 2007, Neurogenetics.
[83] I. Simpson,et al. Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis , 2003, Heart.
[84] Scott M. Williams,et al. New strategies for identifying gene-gene interactions in hypertension , 2002, Annals of medicine.
[85] R. Mayeux,et al. Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease , 2006, Neuroscience Letters.
[86] H. Arai,et al. α1-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease , 2005, Journal of neural transmission.
[87] R. Stewart,et al. Assessment of association between mitochondrial aldehyde dehydrogenase polymorphism and Alzheimer’s disease in an older Korean population , 2004, Neurobiology of Aging.
[88] N. Craddock,et al. Polymorphism in AACT gene may lower age of onset of Alzheimer's disease , 1996, Neuroreport.
[89] D. Allison,et al. Detection of gene x gene interactions in genome-wide association studies of human population data. , 2007, Human heredity.
[90] D. Mann,et al. Silas Weir Mitchell and the “rest cure” , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[91] O. Combarros,et al. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE ε4 allele , 2006, Journal of Neurology.
[92] S. Poduslo,et al. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer’s disease , 2006, Journal of Medical Genetics.
[93] A. Hofman,et al. Polymorphisms in the interleukin 6 and transforming growth factor β1 gene and risk of dementia The Rotterdam Study , 2006, Neuroscience Letters.
[94] P. S. St George-Hyslop,et al. The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. , 2002, American journal of human genetics.
[95] A. Padovani,et al. Association analysis between anterior-pharynx defective-1 genes polymorphisms and Alzheimer's disease , 2003, Neuroscience Letters.
[96] A. Fagan,et al. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β , 2005, Neurobiology of Disease.
[97] H. Feldman,et al. Cholesterol in Alzheimer's disease , 2005, The Lancet Neurology.
[98] J. Ioannidis,et al. Replication validity of genetic association studies , 2001, Nature Genetics.
[99] A. Weverling-Rijnsburger,et al. Patients with Alzheimer's disease display a pro-inflammatory phenotype , 2001, Experimental Gerontology.
[100] A. Mannermaa,et al. MPO and APOEε4 polymorphisms interact to increase risk for AD in Finnish males , 2000, Neurology.
[101] D. Feinstein,et al. Noradrenergic regulation of inflammatory gene expression in brain , 2002, Neurochemistry International.
[102] O. Combarros,et al. Gene–gene interaction between interleukin-6 and interleukin-10 reduces AD risk , 2004, Neurology.
[103] D. Galimberti,et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD , 2005, Annals of neurology.
[104] J. H. Moore,et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.
[105] O. Combarros,et al. Genetic Association of CYP46 and Risk for Alzheimer’s Disease , 2004, Dementia and Geriatric Cognitive Disorders.
[106] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[107] L. Polito,et al. The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-ε4 non-carriers in the Italian Alzheimer’s disease population and does not affect the plasma Aβ(1–42) level , 2007, Neurobiology of Disease.
[108] C. Geula,et al. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia , 1994, Annals of neurology.
[109] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[110] F. Jessen,et al. Confirmation of the association between bleomycin hydrolase genotype and Alzheimer's disease , 2000, Molecular Psychiatry.
[111] E R Martin,et al. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. , 2005, American journal of human genetics.
[112] A. Ritchie,et al. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer’s disease , 2005, Neurobiology of Aging.
[113] T. Isobe,et al. Processing of amyloid beta-peptides by neutral cysteine protease bleomycin hydrolase. , 2006, Protein and peptide letters.
[114] A. Hofman,et al. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer’s disease , 2007, Neurogenetics.
[115] Zhenxin Zhang,et al. Association of α2-macroglobulin polymorphisms and Alzheimer disease in Mainland Han Chinese , 2004, Journal of the Neurological Sciences.
[116] C. Lukacs,et al. Alzheimer’s Peptide Aβ1–42 Binds to Two β-Sheets of α1-Antichymotrypsin and Transforms It from Inhibitor to Substrate* , 1998, The Journal of Biological Chemistry.
[117] W. Streit,et al. Chemokines and Alzheimer’s disease , 2001, Neurobiology of Aging.
[118] M. Gold,et al. No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. , 1997, American journal of medical genetics.
[119] Marylyn D. Ritchie,et al. Multilocus Analysis of Hypertension: A Hierarchical Approach , 2004, Human Heredity.
[120] J. Haines,et al. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K) , 1999, Neuroscience Letters.
[121] Y. Ohnishi,et al. Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. , 2001, American journal of human genetics.
[122] J. Emparanza,et al. Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population , 2007, Neurobiology of Aging.
[123] H. Wiebusch,et al. Further evidence for a synergistic association between APOEɛ4 and BCHE-K in confirmed Alzheimer’s disease , 1999, Human Genetics.
[124] S. Antonarakis,et al. Specific BACE1 genotypes provide additional risk for late‐onset alzheimer disease in APOE ε4 carriers , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[125] O. Combarros,et al. Association of genetic variants of ABCA1 with Alzheimer's disease risk , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[126] F. Panza,et al. Polymorphisms in the oxidized low-density lipoprotein receptor-1 gene and risk of Alzheimer's disease. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.
[127] Jonathan L Haines,et al. Genetics, statistics and human disease: analytical retooling for complexity. , 2004, Trends in genetics : TIG.
[128] L. Farrer,et al. Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD , 2002, Molecular Psychiatry.
[129] R. Tanzi,et al. Clearance of Alzheimer's Aβ PeptideThe Many Roads to Perdition , 2004 .
[130] W. McIntire,et al. The G Protein β Subunit Is a Determinant in the Coupling of Gs to the β1-Adrenergic and A2a Adenosine Receptors* , 2001, The Journal of Biological Chemistry.
[131] C. Caltagirone,et al. Glutathione S-Transferase P1 *C Allelic Variant Increases Susceptibility for Late-Onset Alzheimer Disease: Association Study and Relationship with Apolipoprotein E ε4 Allele , 2005 .
[132] T. Kita,et al. Role of Oxidized LDL in Atherosclerosis , 2001, Annals of the New York Academy of Sciences.
[133] Bosheng Zhang,et al. Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients , 2005, Neuroreport.
[134] O. Combarros,et al. Genetic interaction between two apolipoprotein E receptors increases Alzheimer's disease risk , 2006, Journal of Neurology.
[135] D. Healy. Case-control studies in the genomic era: a clinician's guide , 2006, The Lancet Neurology.
[136] Mitsutoshi Yamamoto,et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[137] J. Ioannidis,et al. Meta-analysis of the association of the cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer's disease: a HuGE gene-disease association review. , 2004, American journal of epidemiology.
[138] S. DeKosky,et al. Association of 3′-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer’s disease , 2003, Journal of medical genetics.
[139] Thomas A Trikalinos,et al. Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.
[140] W. Park,et al. Choline acetyltransferase G +4 A polymorphism confers a risk for Alzheimer’s disease in concert with Apolipoprotein E ε4 , 2004, Neuroscience Letters.
[141] M. Pearce,et al. Gene–gene interaction in folate-related genes and risk of neural tube defects in a UK population , 2004, Journal of Medical Genetics.
[142] E. Corder,et al. Cystatin C as a risk factor for Alzheimer disease , 2005, Neurology.
[143] C. Kumana,et al. Association studies of genetic polymorphisms and complex disease , 2000, The Lancet.
[144] C. Bell. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders , 1994 .
[145] Marylyn D Ritchie,et al. Renin-Angiotensin System Gene Polymorphisms and Atrial Fibrillation , 2004, Circulation.
[146] O. Combarros,et al. Interaction between Poly(ADP-Ribose) Polymerase 1 and Interleukin 1A Genes Is Associated with Alzheimer’s Disease Risk , 2007, Dementia and Geriatric Cognitive Disorders.
[147] L. Feuk,et al. Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene , 2000, Human Genetics.
[148] S. Sorbi,et al. Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease. , 2005, Alzheimer disease and associated disorders.
[149] S. DeKosky,et al. Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12 , 2002, Human Genetics.
[150] W. Maier,et al. Polymorphism in the BACE gene influences the risk for Alzheimer's disease , 2003, Neuroreport.
[151] C. Plata-salamán,et al. Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.
[152] G. Forloni,et al. PEN–2 gene mutation in a familial Alzheimer’s disease case , 2005, Journal of Neurology.
[153] J. H. Moore,et al. Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus , 2004, Diabetologia.
[154] J. Haines,et al. Association between bleomycin hydrolase and Alzheimer's disease in caucasians , 1998, Annals of neurology.
[155] A. Quattrone,et al. Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. , 2004, Archives of neurology.
[156] D. Cox,et al. Additive and multiplicative models for the joint effect of two risk factors. , 2005, Biostatistics.
[157] K. Ishii,et al. Polymorphism of the regulatory region of the presenilin-2 gene in sporadic Alzheimer's disease: A case-control study , 2006, Journal of the Neurological Sciences.
[158] S. DeKosky,et al. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease , 2002, Neuroscience Letters.
[159] A. Nunomura,et al. Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.
[160] Antonio S. Tutor,et al. Polymorphism in genes involved in adrenergic signaling associated with Alzheimer’s , 2004, Neurobiology of Aging.
[161] A. Soltanzadeh,et al. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease , 2004, Neuroscience Letters.
[162] D. Goldstein,et al. Association of genetic loci: Replication or not, that is the question , 2004, Neurology.
[163] Onofre Combarros,et al. Gene-gene interaction between interleukin-1A and interleukin-8 increases Alzheimer’s disease risk , 2004, Journal of Neurology.
[164] B. Staels,et al. Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis , 1999 .
[165] Dc Washington. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .
[166] S. Sorbi,et al. Association of IL10 promoter polymorphism in Italian Alzheimer's disease , 2007, Neuroscience Letters.
[167] B. Hyman,et al. Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. , 2000, Archives of neurology.
[168] O. Combarros,et al. The myeloperoxidase gene in Alzheimer's disease: a case-control study and meta-analysis , 2002, Neuroscience Letters.
[169] S. DeKosky,et al. No association of dynamin binding protein (DNMBP) gene SNPs and Alzheimer's disease , 2008, Neurobiology of Aging.
[170] R. Petersen,et al. Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers , 2002, Neuroscience Letters.
[171] Mitsutoshi Yamamoto,et al. No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[172] Shifts in angiotensin I converting enzyme insertion allele frequency across Europe: implications for Alzheimer’s disease risk , 2003, Journal of neurology, neurosurgery, and psychiatry.
[173] D. Praticò,et al. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.
[174] H. Soininen,et al. Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology , 2003, Neuroscience Letters.
[175] Toshio Ogihara,et al. α1‐Antichymotrypsin as a risk modifier for late‐onset Alzheimer's disease in Japanese apolipoprotein E ε4 allele carriers , 1997 .
[176] P. Amouyel,et al. Impact of the matrix metalloproteinase MMP-3 on dementia , 2007, Neurobiology of Aging.
[177] S. Sevush,et al. Association between Alzheimer's Disease and a Functional Polymorphism in the Myeloperoxidase Gene , 2001, Experimental Neurology.
[178] K. Morgan,et al. Microsatellite polymorphism of the α1-antichymotrypsin gene locus associated with sporadic Alzheimer’s disease , 1996, Human Genetics.
[179] W. Maier,et al. Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer’s disease , 2003, Journal of Neural Transmission.
[180] S. DeKosky,et al. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease , 1998, Nature Genetics.
[181] B. Hyman,et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease , 2004, Journal of neurochemistry.
[182] C. Dingwall,et al. In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase , 2000, Trends in Neurosciences.
[183] Zhenxin Zhang,et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer's disease (AD) in mainland Chinese , 2005, Neuroscience Letters.
[184] R. Tanzi,et al. Clearance of Alzheimer's Aβ Peptide The Many Roads to Perdition , 2004, Neuron.
[185] D. Middleton,et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study , 2001, The Lancet.